Lyra Therapeutics Inc (LYRA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
CEO:
Maria Palasis
Employees:
60
480 ARSENAL STREET, WATERTOWN, MA 02472
617-373-4600

Lyra Therapeutics, Inc. focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial.

Data derived from most recent annual or quarterly report
Market Cap 62.063 Million Shares Outstanding31.827 Million Avg 30-day Volume 36.125 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.4
Price to Revenue113.6784 Debt to Equity0.0 EBITDA-53.666 Million
Price to Book Value1.9791 Operating Margin-3375.7855999999997 Enterprise Value74.613 Million
Current Ratio8.249 EPS Growth-1.188 Quick Ratio8.053
1 Yr BETA 0.2527 52-week High/Low 8.18 / 1.91 Profit Margin-3367.8373
Operating Cash Flow Growth-108.5136 Altman Z-Score0.962 Free Cash Flow to Firm -32.63 Million
View SEC Filings from LYRA instead.

View recent insider trading info

Lyra Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding LYRA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LYRA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-28 by BISHOP JOHN E
  • 3: filed on 2023-02-28 by BISHOP JOHN E
  • 4: filed on 2023-02-02 by RICHARD ROBERT E.
  • 4: filed on 2023-02-02 by WAKSAL HARLAN
  • 4: filed on 2023-02-02 by NOYES CORINNE
  • 4: filed on 2023-02-02 by CAVALIER JASON
  • 4: filed on 2023-02-02 by PALASIS MARIA
  • 4: filed on 2023-02-02 by NIEMAN RICHARD
  • 4: filed on 2022-07-12 by NIEMAN RICHARD
  • 3: filed on 2022-07-12 by NIEMAN RICHARD

    • Events (8k)

  • 8-K: filed on 2022-11-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-26:
    Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
  • 8-K: filed on 2022-09-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-31:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BISHOP JOHN E CHIEF TECHNOLOGY OFFICER

    • Officer
    		 0 2023-02-27 2

    WAKSAL HARLAN EXECUTIVE CHAIR

    • Officer
    • Director
    		 0 2023-01-31 3

    PALASIS MARIA PRESIDENT & CEO

    • Officer
    • Director
    		 0 2023-01-31 1

    NOYES CORINNE SEE REMARKS

    • Officer
    		 36,667 2023-01-31 1

    RICHARD ROBERT E. SVP, TECHNICAL OPERATIONS

    • Officer
    		 30,000 2023-01-31 1

    CAVALIER JASON CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-01-31 1

    NIEMAN RICHARD CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-01-31 3

    ANDERSON EDWARD T

    • Director
    • 10% Owner
    		 7,250 2022-06-16 2

    MERRIFIELD C ANN

    • Director
    		 7,250 2022-06-16 3

    SMITH W BRADFORD

    • Director
    		 7,250 2022-06-16 1

    SNYDERMAN NANCY LYNN MD

    • Director
    		 7,250 2022-06-16 1

    POUKALOV KONSTANTIN

    • Director
    		 7,250 2022-06-16 1

    ALTMAN MICHAEL SETH

    • Director
    		 7,250 2022-06-16 1

    NBVM GP, LLC

    DAMORE RICHARD A

    NORTH BRIDGE VENTURE PARTNERS V A LP

    NORTH BRIDGE VENTURE PARTNERS V-B LP

    NORTH BRIDGE VENTURE PARTNERS VI L P

    NORTH BRIDGE VENTURE MANAGEMENT V, L.P.

    NORTH BRIDGE VENTURE MANAGEMENT VI, L.P.

    • 10% Owner
    		 4,083,000 2022-04-12 1

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    PERCEPTIVE LS (A), LLC

    EDELMAN JOSEPH

    • Director
    • 10% Owner
    		 9,146,731 2022-04-12 1

    TOBIN JAMES R

    • Director
    		 0 2022-03-04 0

    NELSON PAMELA E. SVP, REGULATORY AFFAIRS

    • Officer
    		 30,000 2022-02-12 0

    ELSEY R DON CFO, TREASURER & SECRETARY

    • Officer
    		 0 2021-02-08 0

    POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

    POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

    POLARIS VENTURE PARTNERS V, L.P.

    POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

    POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

    MCGUIRE TERRANCE

    FLINT JONATHAN A

    • 10% Owner
    		 3,169,298 2020-05-05 0

    POLARIS VENTURE MANAGEMENT CO IV LLC

    POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP

    POLARIS VENTURE PARTNERS IV LP

    • 10% Owner
    		 322,920 2020-05-05 0

    WHITESIDES GEORGE M

    • Director
    		 55,064 2020-05-05 0

    LANGER ROBERT

    • Director
    		 15,167 2020-05-05 0

    SOLEUS PRIVATE EQUITY GP I, LLC

    SOLEUS PRIVATE EQUITY FUND I, L.P.

    SOLEUS PE GP I, LLC

    SOLEUS CAPITAL MASTER FUND, L.P.

    SOLEUS CAPITAL, LLC

    SOLEUS CAPITAL GROUP, LLC

    LEVY GUY

    • 10% Owner
    		 No longer subject to file 2020-05-05 0

    ROBERTS CARMICHAEL

    • 10% Owner
    		 No longer subject to file 2020-05-05 0

    PERCEPTIVE ADVISORS LLC

    EDELMAN JOSEPH

    • Director
    • 10% Owner
    		 0 2020-04-30 0

    MOTT RICHARD W

    • 10% Owner
    		 50,462 2020-04-30 0

    SOLEUS PRIVATE EQUITY GP I, LLC

    SOLEUS PRIVATE EQUITY FUND I, L.P.

    SOLEUS PE GP I, LLC

    LEVY GUY

    • 10% Owner
    		 0 2020-04-30 0

    EDGERLY-PFLUG LAURA SEE REMARKS

    • Officer
    		 0 2020-04-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BISHOP JOHN E - Officer CHIEF TECHNOLOGY OFFICER

    		2023-02-28 16:10:19 -0500 2023-02-27 A 220,000 a 220,000 direct

    PALASIS MARIA - Director - Officer PRESIDENT & CEO

    		2023-02-02 17:09:55 -0500 2023-01-31 A 250,000 a 250,000 direct

    CAVALIER JASON - Officer CHIEF FINANCIAL OFFICER

    		2023-02-02 17:11:23 -0500 2023-01-31 A 140,000 a 140,000 direct

    NOYES CORINNE - Officer SEE REMARKS

    		2023-02-02 17:12:56 -0500 2023-01-31 A 36,667 a 36,667 direct -1.8182 -6.5455 -29.0909 0.0 1 -29.0909 26

    NOYES CORINNE - Officer SEE REMARKS

    		2023-02-02 17:12:56 -0500 2023-01-31 A 55,000 a 55,000 direct

    NIEMAN RICHARD - Officer CHIEF MEDICAL OFFICER

    		2023-02-02 17:08:35 -0500 2023-01-31 A 55,537 a 55,537 direct

    WAKSAL HARLAN - Director - Officer EXECUTIVE CHAIR

    		2023-02-02 17:19:30 -0500 2023-01-31 A 200,000 a 200,000 direct

    RICHARD ROBERT E. - Officer SVP, TECHNICAL OPERATIONS

    		2023-02-02 17:41:08 -0500 2023-01-31 A 30,000 a 30,000 direct -1.8182 -6.5455 -29.0909 0.0 1 -29.0909 26

    RICHARD ROBERT E. - Officer SVP, TECHNICAL OPERATIONS

    		2023-02-02 17:41:08 -0500 2023-01-31 A 45,000 a 45,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    LYRA THERAPEUTICS INC LYRA 2023-03-24 22:15:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 21:45:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 21:15:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 20:45:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 20:15:04 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 19:45:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 19:15:04 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 18:45:04 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 18:15:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 17:45:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 17:15:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 16:45:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 16:15:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 15:45:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 15:15:03 UTC 2.5055 2.3145 55000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 14:45:03 UTC 2.5055 2.3145 100000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 14:15:03 UTC 2.5055 2.3145 100000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 13:45:03 UTC 2.4618 2.1082 100000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 13:15:04 UTC 2.4618 2.1082 100000
    LYRA THERAPEUTICS INC LYRA 2023-03-24 12:45:03 UTC 2.4618 2.1082 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments